R
Regeneron Pharmaceuticals
A leading biotechnology company that invents, develops, and commercializes life-transforming medicines for people with serious diseases
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a prominent biotechnology company that has been at the forefront of medical innovation for over 35 years. The company specializes in developing life-transforming medicines for individuals suffering from serious diseases. Regeneron operates in the biopharmaceutical market, focusing on research, development, and commercialization of treatments for conditions such as cancer, eye diseases, allergic and inflammatory diseases, and infectious diseases.
Regeneron's business model is centered around leveraging its proprietary technologies and extensive research capabilities to discover and develop new therapies. The company collaborates with various academic and research institutions, as well as other pharmaceutical companies, to enhance its research and development efforts. These collaborations help Regeneron to stay at the cutting edge of scientific and technological advancements.
The company generates revenue primarily through the sale of its approved medicines. Additionally, Regeneron earns income from licensing its technologies and entering into strategic partnerships. These partnerships often involve co-development and co-commercialization agreements, which allow Regeneron to share both the costs and profits associated with bringing new treatments to market.
Regeneron's clients include healthcare providers, hospitals, and clinics that administer its medicines to patients. The company also works closely with regulatory agencies to ensure that its products meet stringent safety and efficacy standards.
In summary, Regeneron Pharmaceuticals is a leader in the biotechnology sector, dedicated to developing innovative treatments for serious diseases. The company’s success is driven by its strong research and development capabilities, strategic partnerships, and commitment to improving patient outcomes.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1988
- Headquarters
- Town of Mount Pleasant, United States
- Listing
- IPO 1991
- Employees
- 17,086
- Open positions
- 672
- Dealroom signal
- 81.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, DNA, Cardiology and cardiovascular, Genetics and genomics, Genome Engineering, Biotech and Pharma
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 13 companies, latest Jun 2026
- Capital deployed
- $652M
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Jul 2024 | $2M | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Oct 2023 | $5M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Regeneron Pharmaceuticals is 230K monthly website visits, up 43.8% over the last three months. Regeneron Pharmaceuticals's team grew 40.7% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Parabilis MedicinesCambridge, United StatesDeveloping helical peptide therapeutics targeting hard-to-drug disease proteins
$3.5Bvaluation
Tessera TherapeuticsSomerville, United StatesA new genome engineering technology that writes therapeutic messages into the genome to treat diseases at their source
$1.5Bvaluation
23andMeSunnyvale, United StatesHelping people access, understand, and benefit from the human genome
$150Mvaluation
TruvetaBellevue, United StatesTruveta will enable researchers to find cures faster, empower every clinician to be an expert, & help families make the most informed decisions about their care
$1Bvaluation
OxularOxford, United KingdomLong-acting retinal therapies delivered via suprachoroidal space
$148Mvaluation
Mammoth BiosciencesBrisbane, United StatesThe CRISPR-based platform for disease detection
$1Bvaluation
Decibel TherapeuticsBoston, United StatesPioneering inner ear research to deliver life-changing medicines for hearing and balance
$58Mvaluation
VyriadRochester, United StatesOncolytic virus therapies for targeted cancer treatment
$148Mvaluation
Checkmate PharmaceuticalsCambridge, United StatesDeveloping a new approach for cancer immunotherapy
$340Mvaluation
ISA PharmaceuticalsLeiden, NetherlandsDeveloping rationally designed, fully synthetic immunotherapeutics against cancer and persistent viral infections
$114Mvaluation
Alnylam PharmaceuticalsCambridge, United StatesDevelops novel therapeutics-based RNAi and provides overviews of recent drug development programs
$31Bvaluation
ArcheMedXCharlottesville, United StatesHealthcare informatics and e-learning technology company that is transforming online learning in medicine through an agile
$10Mvaluation
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
HHS Administration for Strategic Preparedness and Response
Series B and later1 investor entered at this stage
US Department of Health and Human Services
Other known investors3 additional known investors
International Biotechnology Trust
Nordic Biotech
US Biomedical Advanced Research and Development Authority
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Regeneron Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Regeneron Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.